glycerol phenylbutyrate (ravicti) Report issue

Small molecule Orphan Drug FDA Approved FDA Fast Track FDA

Active Ingredient History

  • Now
Glycerol phenylbutyrate (USAN), trade name Ravicti, is a medication used in the treatment of certain inborn urea cycle disorders. The medication works by preventing the harmful buildup of ammonia in the body. It is an FDA-approved prescription drug in the US. It is approved for anyone over 2 months of age. It was developed by Hyperion Therapeutics based on the existing drug Buphenyl, and received approval on February 1, 2013. Hyperion has been criticized for setting a high price for the drug. The price was set at US$250,000–290,000. In 2014, the drug generated $30.8 million in net sales, far behind the older and less expensive Buphenyl. In March 2015, Horizon Pharma acquired Hyperion Therapeutics and thus Raviciti.   Wikipedia

  • SMILES: O=C(CCCc1ccccc1)OCC(COC(=O)CCCc2ccccc2)OC(=O)CCCc3ccccc3
  • Mol. Mass: 530.66
  • ALogP: 6.05
  • ChEMBL Molecule:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: Yes

Drug Pricing (per unit)

United States

$138.7932 - $191.5364
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

glycerol phenylbutyrate | glyceryl tri-4-phenylbutyrate | gpb | gt4p | hpn100 | hpn 100 | hpn-100 | ravicti


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue